Fresenius Med. Care: Solid organic growth but US margins affected
BUY, Fair Value EUR53.5 (+11%)
Fresenius Medical Care released mixed Q2 figures with strong organic growth of 5% (Q1: 4%) while margins were affected by higher operating expenses in the US. US dialysis care grew 6% (4% same store growth) with revenue per treatment at USD355 (-1.1% sequentially, +0.9% y/y) a strong resistance despite the implementation of sequestration in Q2. Dialysis products (+5% CER) rebounded following a weak Q1 (+2% CER) with growth in the US and internationally. With sales in line with consensus, disappointment comes from margins which were roughly 4% below expectations mainly driven by an increase in SG&A in the US. There is no doubt that the Global efficiency plan that FMC is launching will be under scrutiny. Sales guidance is maintained (USD>14.6bn) while net income guidance is slightly adjusted in the lower range at USD1.1bn-USD1.15bn but we do not expect major figure revisions. One focus of the conference call should definitely be on proposed Medicare cuts as well as the cost efficiency programme.
Full report available to subscribers
Please contact firstname.lastname@example.org